Sec Form 13D Filing - Foris Ventures LLC filing for AMYRIS INC. (AMRS) - 2023-06-09

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 8)*

AMYRIS, INC.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

03236M200

(CUSIP Number)

Barbara Hager

c/o Foris Ventures, LLC

1180 San Carlos Avenue, #717

San Carlos, CA 94070

650-384-0240

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

COPY TO:

Jon M. Novotny, Esq.

c/o Goodwin Procter LLP

Three Embarcadero Center

San Francisco, CA 94111

(415) 733-6000

June 5, 2023

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box  ☐

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

This Amendment No. 8 (“Amendment No. 8”) to Schedule 13D amends the statement on Schedule 13D filed with the United States Securities and Exchange Commission on October 30, 2017, as amended by Amendment No. 1 thereto filed on August 28, 2018, Amendment No. 2 thereto filed on July 18, 2019, Amendment No. 3 thereto filed on September 8, 2022, Amendment No. 4 thereto filed on September 15, 2022, Amendment No. 5 thereto filed on January 9, 2023, Amendment No. 6 thereto filed on March 17, 2023 and Amendment No. 7 thereto filed on May 24, 2023 (collectively and as amended, the “Schedule 13D”), relating to the Common Stock. This Amendment No. 8 is being filed by Foris Ventures, LLC, Vallejo Ventures Trust, L. John Doerr, Ann Doerr, and Barbara Hager (collectively, the “Reporting Persons”).

The Items below amend the information disclosed under the corresponding Items of the Schedule 13D as described below. Except as specifically provided herein, this Amendment No. 8 does not modify any of the information previously reported in the Schedule 13D.

ITEM 4. PURPOSE OF TRANSACTION.

Item 4 of the Schedule 13D is supplemented by the following:

Anesma Loan Agreement

On June 5, 2023, the Company, certain of the Company’s subsidiaries (the “Subsidiary Guarantors”), and Anesma Group, LLC (“Anesma”), an affiliate of FV, as lender, entered into a Loan and Security Agreement (the “Anesma Loan Agreement”) to make available to the Company a secured term loan facility in an aggregate principal amount of up to $50 million (the “Anesma Loan Facility”), of which $25 million was drawn on June 5, 2023. Until June 30, 2023, the Company has the right under the Loan Agreement to request an additional advance not to exceed the cashflow requirements of the Company as determined by Anesma for the three-calendar week period immediately following the proposed advance date, subject to a maximum of $25 million in the aggregate.

The Anesma Loan Facility matures on June 15, 2024. Loans under the Anesma Loan Facility will accrue interest at a rate of 12% per annum. Interest is capitalized when due, on the first business day of each calendar quarter beginning with the calendar quarter starting after the advance date of any advance.

The obligations under the Anesma Loan Facility are (i) guaranteed by the Subsidiary Guarantors, and (ii) secured by a perfected first lien security interest in substantially all of the assets of the Company and the Subsidiary Guarantors, in each case subject to certain limitations and exclusions.

Prepayment of the outstanding amounts under the Anesma Loan Facility will be required upon the occurrence of a change of control of the Company, as specified in the Anesma Loan Agreement. In addition, the Company may at its option prepay the outstanding principal amount of the loans under the Anesma Loan Facility before the maturity date of such loans without the incurrence of a prepayment fee.

The representations, covenants, and events of default in the Anesma Loan Agreement are customary for financing transactions of this nature. If any payment under the Anesma Loan Facility is not made when due, an amount equal to 3% of the past due amount shall be payable on demand. In addition, upon the occurrence and during the continuation of an event of default, all principal, interest and other obligations under the Anesma Loan Facility shall bear interest at 12% per annum plus 1%. The Anesma Loan Agreement includes customary affirmative and negative covenants and also contains financial covenants, including the following: (i) the Company shall provide the Lenders on the last business day of each week with (a) a 13-week cash flow forecast for the Company, including, without limitation, consolidated balance sheets, statements of income, and cash flow forecasts, and (b) aged listings of accounts receivable and accounts payable; (ii) As of the last day of each fiscal quarter, the Company and its consolidated entities shall have revenue (determined in accordance with GAAP) of not less than $150,000,000 on a trailing 12 month basis; (iii) on the last Business Day of each week, the Company and the Subsidiary Guarantors shall have, on a consolidated basis, liquidity calculated as (a) unrestricted, unencumbered cash and cash equivalents denominated in dollars in one or more deposit accounts located in the United States, plus (b) any additional amount of available credit, borrowings, or investments readily convertible to cash to the extent necessary, so that the sum of the amounts described in clauses (a) and (b) is not less than $2,000,000; (iv) commencing on June 2, 2023, and on a weekly basis thereafter, the Company shall, or shall cause its financial advisors to, prepare and deliver to the

Lenders cash flow projections, in form and methodology as previously provided to the Lender, showing that the Company and the other Subsidiary Guarantors have adequate liquidity to operate their bu sinesses through and including the calendar year ending December 31, 2023; and (v) the repayment or prepayment of all or any part of Tranche 3 (as defined in the loan agreement by and between DSM Finance B.V. and the Company) on or before April 15, 2024 other than from proceeds of sale of (a) all of the capital stock of Amyris RealSweet, LLC, or (b) the consummation of any sale of any consumer brands from which, in the case of this clause (b), the Company shall receive at least $75,000,000 in gross proceeds, which must, in each case, be on terms acceptable to the Lender in its absolute discretion, shall constitute an event of default (collectively, the “Anesma Covenants”).

Omnibus Amendment Agreement to 2019 LSA, 2022 LSA and Perrara LSA

On June 5, 2023, the Company and certain of the Company’s subsidiaries entered into omnibus amendment agreements (collectively, the “Omnibus Amendment Agreements”) with each of FV and Perrara (the “Lenders”), pursuant to which the Lenders agreed to waive all existing defaults under the following agreements: (i) the 2019 LSA (ii) the 2022 LSA, and (iii) the Loan and Security Agreement (the “Perrara LSA”), dated March 10, 2023 (as amended, restated, supplemented or otherwise modified from time to time), by and among the Company, certain subsidiaries of the Company party thereto, and Perrara. In addition to waiving such defaults, the Lenders agreed to (a) extend the final maturity date of the 2019 LSA to July 1, 2024, (b) extend certain repayment dates under the 2022 LSA such that $50 million will be due and payable on April 15, 2024 and $30 million will be due and payable on the maturity date of June 15, 2024, and (c) extend the repayment and maturity dates under the Perrara LSA such that $12.5 million will be due and payable on April 15, 2024, $12.5 million will be due and payable on June 15, 2024 and $12.5 million will be due and payable on the maturity date of September 15, 2024. Default interest that previously accrued under the 2019 LSA is deemed to accrue until the 2019 LSA maturity date. Default interest that previously accrued under the 2022 LSA and 2023 LSA is deemed to have been paid in kind and added to the outstanding principal amount due on the maturity dates of the 2022 LSA and 2023 LSA, respectively. In addition, the Omnibus Amendment Agreements amend the 2019 LSA, 2022 LSA and Perrara LSA to include covenants substantially similar to the Anesma Covenants.

In exchange for each of the Lenders entering into an Omnibus Amendment Agreement, the Company agreed to certain conditions and covenants, including the Company entering into an amendment to the loan agreement by and between the Company and DSM Finance B.V. and the Company entering into, and incurring indebtedness, pursuant to a loan agreement with Anesma Group, LLC, as described above.

Except as set forth above, all other terms, conditions and rights of the 2019 LSA, 2022 LSA, and Perrara LSA and the related transaction documents remain in full force and effect, which were described in the Company’s prior disclosures.

General

The Reporting Persons acquired the securities described in this Schedule for investment purposes and they intend to review their investments in the Company on a continuing basis. In addition, the Reporting Persons intend to participate in the management of the Company through representation on the Company’s board of directors (the “Board”). L. John Doerr and Ryan Panchadsaram, a partner at Foris Ventures, serve as members of the Board. Any actions the Reporting Persons might undertake will be dependent upon the Reporting Persons’ review of numerous factors, including, but not limited to: an ongoing evaluation of the Company’s business, financial condition, operations and prospects; price levels of the Company’s securities; general market, industry and economic conditions; the relative attractiveness of alternative business and investment opportunities; and other future developments.

The Reporting Persons may, at any time and from time to time, acquire additional securities of the Company, or retain or sell all or a portion of the securities then held, in the open market or in privately negotiated transactions. In addition, the Reporting Persons in discussions with management, the Board, and shareholders of the Company and other relevant parties or encourage such persons to consider or explore extraordinary corporate transactions, such as: a merger; sales or acquisitions of assets or businesses; changes to the capitalization or dividend policy of the Company; restructurings, reorganizations or recapitalizations of the Company, or other material changes to the Company’s business or corporate structure, including changes in management or the composition of the Board.

Other than as described above, none of the Reporting Persons currently has any plans or proposals that relate to, or would result in, any of the matters listed in Items 4(a)–(j) of Schedule 13D, although, depending on the factors discussed herein, the Reporting Persons may change their purpose or formulate different plans or proposals with respect thereto at any time.

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.

Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:

(a)-(b)

The following sets forth, as of the date of this statement, the aggregate number of shares of Common Stock and percentage of Common Stock beneficially owned by each of the Reporting Persons, as well as the number of shares of Common Stock as to which each Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition of, or shared power to dispose or to direct the disposition of, as of the date hereof, based on a total of 402,436,449 shares of Common Stock, which amount consists of (i) 369,385,614 shares of Common Stock issued and outstanding as of May 5, 2023 based on the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, as filed with the SEC on May 10, 2023, (ii) 21,004,799 shares of Common Stock issuable to FV upon conversion of the indebtedness outstanding under the 2019 LSA, including accrued and unpaid interest as of June 5, 2023 and (iii) 12,046,036 shares of Common Stock issuable to FV upon exercise of the 2022 Warrants.

For the purposes of calculating John Doerr’s beneficial ownership only, the percent of class set forth below is based on a total of 402,463,113 based on the Company’s shares of Common Stock, which amount consists of (i) 369,385,614 shares of Common Stock issued and outstanding as of May 5, 2023 based on the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, as filed with the SEC on May 10, 2023, (ii) 21,004,799 shares of Common Stock issuable to FV upon conversion of the indebtedness outstanding under the 2019 LSA, including accrued and unpaid interest as of June 5, 2023, (iii) 12,046,036 shares of Common Stock issuable to FV upon exercise of the 2022 Warrants, (iv) 15,064 shares of Common Stock issuable to John Doerr upon the exercise of stock options exercisable for Common Stock within 60 days of June 5, 2023, and (v) 11,600 shares of Common Stock issuable to John Doerr upon the vesting of restricted stock units within 60 days of June 5, 2023.

The securities reported herein consist of (i) 87,268,358 shares of Common Stock currently outstanding and held by FV, (ii) 21,004,799 shares of Common Stock issuable upon conversion of the indebtedness outstanding under the 2019 LSA, including accrued and unpaid interest as of June 5, 2023, (iii) 12,046,036 shares of Common Stock issuable to FV upon exercise of the 2022 Warrants, (iv) 567 shares of Common Stock held by VVT, (v) 9,648 shares of Common Stock held by Clarus, LLC, (vi) 248,304 shares of Common Stock held by Kleiner Perkins Caufield & Byers XII, LLC and (vii) 4,531 shares of Common Stock held by KPCB XII Founders Fund, LLC, (viii) 3,333,333 shares of Common Stock held by Perrara, (ix) 34,447 shares of Common Stock held by John Doerr, (x) 15,064 shares of Common Stock issuable to John Doerr upon exercise of options within 60 days of June 5, 2023, and (xi) 11,600 shares of Common Stock issuable to John Doerr upon the vesting of restricted stock units within 60 days of June 5, 2023.

As of June 5, 2023, 16,680,334 shares of Common Stock are issuable upon conversion of the indebtedness outstanding under the 2019 LSA in respect of an outstanding principal amount of $50.0 million and 4,324,465 shares of Common Stock are issuable upon conversion of accrued and unpaid interest of $13.0 million, reflecting a fixed conversion price of $3.00 per share of Common Stock. Barbara Hager, the manager of FV, may be deemed to have sole power to vote and dispose of these securities. The 2019 LSA bears interest at 6.0% per annum, subject to certain default interest provisions in the event of a default under the 2019 LSA; interest is not payable until the maturity date of July 1, 2024.

ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER.

Item 6 of the Schedule 13D is hereby amended and restated in its entirety as follows:

The information set forth under Items 4 and 5 and the agreements set forth on the Exhibit attached hereto are incorporated herein by reference. Other than as described herein and in the Schedule 13D, to the best of the knowledge of the Reporting Persons, there are no contracts, arrangements, understandings or relationships (legal or otherwise) between each Reporting Person and any person, with respect to the securities of the Company, including, but not limited to, transfer or voting of any of the securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies, including any securities pledged or otherwise subject to a contingency the occurrence of which would give another person voting power or investment power over such securities other than standard default and similar provisions contained in loan agreements.

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.

Item 7 of the Schedule 13D is hereby supplemented as follows:

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: June 9, 2023